Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of CTS3497 in Patients With MTAP Deficient Advanced Solid Tumors and Lymphomas

NCT06971523 is registered in ClinicalTrials.gov with CytosinLab Therapeutics Co., Ltd. as lead sponsor.

NCT NCT06971523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06971523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of CTS3497 in Patients With MTAP Deficient Advanced Solid Tumors and Lymphomas
Lead sponsor
CytosinLab Therapeutics Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 25, 2024
Completion date
June 30, 2029
Enrollment
224 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, solid tumor